USANA Health Sciences (NYSE:USNA) Updates FY 2021 Earnings Guidance

USANA Health Sciences (NYSE:USNA) updated its FY 2021 earnings guidance on Thursday. The company provided earnings per share guidance of $5.800-$6.000 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $6.350. The company issued revenue guidance of $1.18 billion-$1.20 billion, compared to the consensus revenue estimate of $1.26 billion.USANA Health Sciences also updated its Q3 2021 guidance to $1.280-$1.330 EPS.

A number of equities analysts have recently commented on the company. Tigress Financial reiterated a buy rating and issued a $122.00 price objective on shares of USANA Health Sciences in a research note on Friday, October 8th. Zacks Investment Research upgraded USANA Health Sciences from a sell rating to a hold rating in a research note on Wednesday, September 29th.

USNA stock opened at $97.18 on Thursday. USANA Health Sciences has a twelve month low of $73.00 and a twelve month high of $107.85. The company has a market cap of $1.94 billion, a PE ratio of 14.66 and a beta of 0.85. The business’s 50-day simple moving average is $94.42 and its 200 day simple moving average is $98.19.

USANA Health Sciences (NYSE:USNA) last released its quarterly earnings data on Tuesday, July 27th. The company reported $1.87 earnings per share for the quarter, beating analysts’ consensus estimates of $1.78 by $0.09. The company had revenue of $336.84 million for the quarter, compared to the consensus estimate of $340.20 million. USANA Health Sciences had a return on equity of 33.65% and a net margin of 11.09%. Research analysts predict that USANA Health Sciences will post 6.31 EPS for the current fiscal year.

In other news, Director Gilbert A. Fuller sold 312 shares of USANA Health Sciences stock in a transaction that occurred on Thursday, August 5th. The shares were sold at an average price of $96.52, for a total value of $30,114.24. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Robert A. Sinnott sold 1,648 shares of USANA Health Sciences stock in a transaction that occurred on Monday, August 16th. The shares were sold at an average price of $95.04, for a total transaction of $156,625.92. Following the completion of the transaction, the insider now owns 1,648 shares of the company’s stock, valued at approximately $156,625.92. The disclosure for this sale can be found here. Insiders have sold 3,435 shares of company stock worth $331,837 over the last ninety days. Company insiders own 0.21% of the company’s stock.

USANA Health Sciences Company Profile

USANA Health Sciences, Inc develops and manufactures nutritional, personal care and weight-management products. Its product line divided into four categories: Essentials, Optimizers, Foods, Personal Care and Skincare, and All Other. The Essentials Nutritionals category includes vitamin and mineral supplements that provide a foundation of advanced total body nutrition for every age group.

Recommended Story: Growth Stocks

Earnings History and Estimates for USANA Health Sciences (NYSE:USNA)

Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with's FREE daily email newsletter.